NCT01717287View on ClinicalTrials.gov

A Study of the Safety, Tolerability, and Antiretroviral Activity of Raltegravir (MK-0518) in Combination With Other Antiretroviral Therapies in Russian Children and Adolescents Infected With Human Immunodeficiency Virus (HIV-1) (MK-0518-248)

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

November 16, 2012

Primary Completion Date

December 11, 2013

Study Completion Date

December 11, 2013

Conditions
HIV Infection
Interventions
DRUG

Raltegravir Film-coated Tablet

DRUG

Raltegravir Chewable Tablet

DRUG

Other Anti-Retroviral Therapy

At baseline, the investigator selected the other anti-retroviral therapies to be used in combination with raltegravir based on current treatment guidelines, the participant's treatment history, and prior anti-retroviral resistance testing

Sponsors

Collaborators (1)

Covance
All Listed Sponsors
collaborator

Covance

INDUSTRY

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01717287 - A Study of the Safety, Tolerability, and Antiretroviral Activity of Raltegravir (MK-0518) in Combination With Other Antiretroviral Therapies in Russian Children and Adolescents Infected With Human Immunodeficiency Virus (HIV-1) (MK-0518-248) | Biotech Hunter | Biotech Hunter